Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function—value of the wearable cardioverter/defibrillator

The true incidence of life‐threatening ventricular tachyarrhythmic events and the risk of sudden cardiac death in the early stage of peripartum cardiomyopathy (PPCM) are still unknown. We aimed to assess the usefulness of the wearable cardioverter/defibrillator (WCD) to bridge a potential risk for life‐threatening arrhythmic events in patients with early PPCM, severely reduced left ventricular ejection fraction (LVEF) and symptoms of heart failure.

[1]  Seung‐Jung Park.  Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction , 2015 .

[2]  E. Arbustini,et al.  The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[3]  Arthur J Moss,et al.  Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator. , 2013, European heart journal.

[4]  K. Sliwa,et al.  Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy , 2013, Basic Research in Cardiology.

[5]  K. Sliwa,et al.  Predictors of outcome in 176 South African patients with peripartum cardiomyopathy , 2012, Heart.

[6]  W. Stevenson,et al.  Catheter Ablation of Ventricular Tachycardia in Nonischemic Heart Disease , 2012, Circulation. Arrhythmia and electrophysiology.

[7]  M. Josephson,et al.  Sudden cardiac death and implantable cardioverter defibrillators: two modern epidemics? , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[8]  S. Szymkiewicz,et al.  Wearable defibrillator in congenital structural heart disease and inherited arrhythmias. , 2011, The American journal of cardiology.

[9]  K. Sliwa,et al.  Long-term outcome of peripartum cardiomyopathy in a population with high seropositivity for human immunodeficiency virus. , 2011, International journal of cardiology.

[10]  Mark E. Anderson,et al.  Sudden Cardiac Death Prediction and Prevention: Report From a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop , 2010, Circulation.

[11]  K. Collins,et al.  Use of a Wearable Automated Defibrillator in Children Compared to Young Adults , 2010, Pacing and clinical electrophysiology : PACE.

[12]  K. Sliwa,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy , 2010, European journal of heart failure.

[13]  M. Chung,et al.  Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. , 2010, Journal of the American College of Cardiology.

[14]  E. Saarel,et al.  Use of the Wearable External Cardiac Defibrillator in Children , 2010, Pacing and clinical electrophysiology : PACE.

[15]  S. Szymkiewicz,et al.  Bridging a Temporary High Risk of Sudden Arrhythmic Death. Experience with the Wearable Cardioverter Defibrillator (WCD) , 2010, Pacing and clinical electrophysiology : PACE.

[16]  H. Figulla,et al.  Successful use of a wearable cardioverter-defibrillator in myocarditis with normal ejection fraction , 2010, Clinical Research in Cardiology.

[17]  S. Goland,et al.  Clinical profile and predictors of complications in peripartum cardiomyopathy. , 2009, Journal of cardiac failure.

[18]  G. Kay,et al.  Ventricular arrhythmias originating from the epicardial ventricular outflow tract complicated with peripartum cardiomyopathy , 2009, Journal of Interventional Cardiac Electrophysiology.

[19]  R. Passman,et al.  American Heart Association/american College of Cardiology Foundation/heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardi , 2008, Heart rhythm.

[20]  K. Sliwa,et al.  Reversal of IFN‐γ, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy , 2008, European journal of heart failure.

[21]  C. Tracy,et al.  Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. , 2006 .

[22]  Dan M. Roden,et al.  ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines , 2006 .

[23]  K. Sliwa,et al.  Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. , 2006, European heart journal.

[24]  L. Christie,et al.  Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. , 2005, Mayo Clinic proceedings.

[25]  J. Fett.  Pregnancy-related mortality due to cardiomyopathy: United States, 1991-1997. , 2004, Obstetrics and gynecology.

[26]  C. Berg,et al.  Pregnancy‐Related Mortality Due to Cardiomyopathy: United States, 1991–1997 , 2003, Obstetrics and gynecology.

[27]  S. Szymkiewicz,et al.  Clinical Efficacy of a Wearable Defibrillator in Acutely Terminating Episodes of Ventricular Fibrillation Using Biphasic Shocks , 2003, Pacing and clinical electrophysiology : PACE.

[28]  S. Szymkiewicz,et al.  Clinical efficacy of the wearable cardioverter-defibrillator in acutely terminating episodes of ventricular fibrillation. , 1998, The American journal of cardiology.

[29]  K. Chee.  Favourable outcome after peripartum cardiomyopathy: a ten-year study on peripartum cardiomyopathy in a university hospital. , 2013, Singapore medical journal.

[30]  S. Szymkiewicz,et al.  Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator. , 2012, Journal of cardiac failure.

[31]  S. Szymkiewicz,et al.  Evaluation of the effectiveness of a wearable cardioverter defibrillator detection algorithm. , 2010, Journal of electrocardiology.

[32]  M. Diao,et al.  [Electrocardiographic recording of long duration (Holter) of 24 hours during idiopathic cardiomyopathy of the peripartum]. , 2004, Archives des maladies du coeur et des vaisseaux.